Zenas BioPharma

Biotech & Life Sciences · Waltham, United States · Founded 2020 · IPO 2024

Zenas BioPharma is a global biopharmaceutical company focused on developing and commercializing immunology-based therapies for patients with autoimmune diseases. The company operates in the biopharmaceutical market, targeting patients in need of innovative treatments for autoimmune conditions. Zenas BioPharma's business model centers on advancing a deep pipeline of therapeutics through successful business development strategies and partnerships. The company generates revenue by developing and commercializing these therapies, aiming to bring transformative solutions to patients worldwide. Zenas BioPharma serves a diverse client base, including healthcare providers, patients, and research institutions, and leverages its experienced leadership team and network of business partners to drive operational excellence. Keywords: autoimmune, therapeutics, biopharmaceutical, immunology, innovative, pipeline, commercialization, partnerships, leadership, global.

Valuation $1.53B

Revenue $36M

Total funding $100–500M

Power Law Thoroughbred$100M+ revenue

Investors

23 investors on Zenas BioPharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 13 investors entered at this stage

Fairmount Funds Management

Tellus BioVentures

Quan Capital

Wellington Management

Enavate Sciences

Xencor

Agent Capital

Perceptive Advisors

Pivotal Life Sciences

Superstring Capital

Rock Springs Capital

Vivo Capital

Longitude Capital

Series B+ 10 investors entered at this stage

Bristol-Myers Squibb

SR One

Norwest Venture Partners

Delos Capital

NEA

Federated Hermes

Pivotal BioVenture Partners

ArrowMark Partners

Royalty Pharma

Pharmakon Holdings

Global footprint

Where Zenas BioPharma has talent and traffic

Workforce by country

7 countries with
team presence

🇺🇸 United States92.5%

🇨🇭 Switzerland2.3%

🇨🇳 China2.3%

🇪🇸 Spain0.8%

🇫🇷 France0.8%

Top 5 of 7 shown

Web traffic by country

9.4K monthly visits
across markets

🇺🇸 United States76.6%

🇬🇧 United Kingdom8.5%

🇮🇳 India8.5%

🇨🇦 Canada6.4%

Top 4 markets shown

Talent graph

The shape of Zenas BioPharma's talent

Dealroom maps Zenas BioPharma's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 team members profilednamed & role-tagged by Dealroom

201 employeestotal headcount

4 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Zenas BioPharma's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$117k patent portfolio · 9 active families

Estimated portfolio value

$117k

<0.01% of market cap · 4171.1× smaller than top peer Genmab ($488M)

9 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Zenas BioPharma

An AI-synthesized read of the highest-engagement posts about Zenas BioPharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zenas BioPharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles